Pan-Asia Catalysts/Events, Quiddity Advisors

Travis Lundy

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

Agricultural Bank Of China / Event-Driven

This is a new H/A Spread monitor project offering a brief look at recent changes in H-Share and A-Share spreads, Southbound flow and impact, and where the spreads are trading within their own historical ranges.
Main notes this week are:
<ul>
<li>HK$13.5bn of net buying by Southbound flows, which was 1.46% of HKEx Turnover - about in line with the previous four full weeks of trading. </li>
<li>Net buying since the last net selling day has been HK$48.8bn, which is not an unusual streak. </li>
<li>Southbound flows in the…</li>
</ul>

This is a new H/A Spread monitor project offering a brief look at recent changes in H-Share and A-Share spreads, Southbound flow and impact, and where the spreads are trading within their own historical ranges.
Main notes this week are:

HK$13.5bn of net buying by Southbound flows, which was 1.46% of HKEx Turnover - about in line with the previous four full weeks of trading. 
Net buying since the last net selling day has been HK$48.8bn, which is not an unusual streak. 
Southbound flows in the…


Quiddity Weekly H/A: Discounts & Southbound Flows 20180126

This is a new H/A Spread monitor project which attempts to give a brief look at recent changes in H-Share and A-Share spreads based on various influences and sector patterns. 
<h2>H-Share/A-Share Discounts, Changes over 1wk, 4wks and Changes in Southbound Flow</h2>
The first set of tables below show...
<ul>
<li class="">the discount of the major H-share listed companies to their respective A-share,</li>
<li class="">the change in discount over 1-week and 4-weeks (positive number means the H has outperformed the A),</li>
<li class="">a measure of decile…</li>
</ul>

This is a new H/A Spread monitor project which attempts to give a brief look at recent changes in H-Share and A-Share spreads based on various influences and sector patterns. 
H-Share/A-Share Discounts, Changes over 1wk, 4wks and Changes in Southbound Flow
The first set of tables below show...

the discount of the major H-share listed companies to their respective A-share,
the change in discount over 1-week and 4-weeks (positive number means the H has outperformed the A),
a measure of decile…


Quiddity Weekly H/A: Shares Discounts & Southbound Flows 20180112

Analyst

Alasdair Moody

Exposing Creative Accounting

Bucephalus Research Partnership

Bucephalus Research Partnership Limited. Exposing Creative Accounting.

At the Bucephalus Research Partnership (BRP) we analyse financial statements using our accountant's practical experience and our own quantitative algorithms for corporate governance, accounting risk and peer performance.

Our thematic research refines our unique algorithms while our single stock research focuses on examples where we discover a significant gap between published accounts and business reality.

​Bucephalus Research Partnership:
- Is an independent fee-based research service
- Does not take proprietary positions, long or short
- Does not solicit business or fees from the corporates we review

Thematic (Sector/Industry)

We examined ten years of accounting and valuation data for the pharmaceutical companies around the world with sales of US$100m+ and created statistics for each region based on aggregate data and for a typical company. In this trend report, we summarise the data and highlight the outliers. Assuming clients will have their own macro industry views, we used valuations and our Governance, Accounting risk and Peer performance (GAP) scores, (which help quantify the risk of creative accounting) to…

We examined ten years of accounting and valuation data for the pharmaceutical companies around the world with sales of US$100m+ and created statistics for each region based on aggregate data and for a typical company. In this trend report, we summarise the data and highlight the outliers. Assuming clients will have their own macro industry views, we used valuations and our Governance, Accounting risk and Peer performance (GAP) scores, (which help quantify the risk of creative accounting) to…

Global Pharmaceuticals: Valuations, Assets and Leverage Up - Margins Down

Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Capital Markets

Sisram Medical is raising up to USD174m in its Hong Kong listing. Sisram Medical is an Israel headquartered meditech company with backing from China-based <a href="https://www.smartkarma.com/entities/8045" target="_blank" data-smartkarma-citation="entities:8045:1">Shanghai Fosun Pharmaceutical (Group) (2196 HK)</a>. In this insight, we will cover the company's background, its growth drivers, financial highlights, and score the deal in our ECM Framework.

Sisram Medical is raising up to USD174m in its Hong Kong listing. Sisram Medical is an Israel headquartered meditech company with backing from China-based Shanghai Fosun Pharmaceutical (Group) (2196 HK). In this insight, we will cover the company's background, its growth drivers, financial highlights, and score the deal in our ECM Framework. 

Sisram Medical IPO: Israeli Technology, China Story

Independent Insight Provider

Stewart Paterson

Macroeconomics

Any analysis of China's credit growth over the past six years or so would suggest that it is unsustainable and that as a result, when the day of reckoning comes, the country and the rest of the world will be hit by another deflationary shock. Indeed, global inflation has started to wane again in recent months (see: <a href="https://www.smartkarma.com/insights/money-matters-the-end-of-reflation" target="_blank" data-smartkarma-citation="insights:10500">Money Matters: The End of Reflation?</a>). Commodities have broadly speaking been weak and base effects mean headline numbers are fading. Investors however have broadly speaking pushed…

Any analysis of China's credit growth over the past six years or so would suggest that it is unsustainable and that as a result, when the day of reckoning comes, the country and the rest of the world will be hit by another deflationary shock. Indeed, global inflation has started to wane again in recent months (see: Money Matters: The End of Reflation?). Commodities have broadly speaking been weak and base effects mean headline numbers are fading. Investors however have broadly speaking pushed…

China

Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. manufactures and sells Chinese patent medicine. The Company also wholesales, retails, imports, and exports Western and Chinese pharmaceutical products and various medical apparatus.

Guangzhou Baiyunshan Pharmaceutical Holdings (874 HK)

Guangzhou Baiyunshan Pharmaceutical Holdings

Changchun High & New Technology Industry (Group) Inc. is an investment holding company.  Through its subsidiaries, the Company manufactures biopharmaceuticals and Chinese traditional medicines, constructs infrastructure facilities, manufactures electrolytic condensers, and develops and manages real estate.

Xizang Haisco Pharmaceutical Group Company Limited develops, manufactures and sells drug formulations and active pharmaceutical ingredients. The Company's main products include hepatobiliary disease medication, anti-infective drugs, parenteral nutrition drugs, invert sugar for injection, and other related products.

Xizang Haisco Pharmaceutical Group Co (002653 CH)

Shenzhen Salubris Pharmaceuticals Co., Ltd. develops, manufactures, and distributes pharmaceutical and healthcare products such as tablets, capsules, injection formulations and active pharmaceutical ingredients.

Shenzhen Salubris Pharmaceuticals A (002294 CH)

Dong-E-E-Jiao Co., Ltd. primarily manufactures and sells traditional Chinese medicine, health care products, health foods, and bio-medicine. The company also engages in gelatin products manufacturing.

Kangmei Pharmaceutical Co., Ltd. develops, produces, and sells medicines that are used for the treatment of high blood pressure and cold.  The Company also pr oduces antibiotic drugs and health care products. Kangmei also sells other manufacturers' medical products through its wholesale and retail chain.

Kangmei Pharmaceutical Co Ltd (600518 CH)

Humanwell Healthcare (Group) Co., Ltd specializes in the R&D and sales of pharmaceuticals, biotechnology, and chemical products, in addition to the import and export of goods and technology. The company, through its subsidiaries, also operate in real estate development and sales, industrial investment and management, and education projects.

Tianjin Zhongxin Pharmaceutical Group Corporation Limited produces and sells traditional Chinese medicine, western medicine, health products, and healthcare instruments.  The Group also manufactures gene-related biopharmaceutical products.  Tianjin Zhongxin markets its products under the Great Wall, Cypress, and Health brand names.

Tianjin Zhongxin Phrmctl Gp Cp (600329 CH)

Shijiangzhuang Yiling Pharmaceutical Co Ltd develops, produces and sells Chinese patent medicine. The Company's major products include Tongxinluo capsules, Shensongyangxin capsules, Lotus Qingwen capsules, Qili Qiangxin capsules and Bazi Bushen capsules.

Shijiazhuang Yiling Pharmaceutical (002603 CH)

Zhejiang Huahai Pharmaceutical Co., Ltd. manufactures and retails pharmaceutical products and medical raw materials. The Company exports its products to many parts of the world.

Zhejiang Huahai Pharmaceutical Co, Ltd. (600521 CH)

Perrigo Company PLC is a global healthcare supplier that develops, manufactures, and distributes OTC and generic prescription pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients and pharmaceutical and medical diagnostic products. The Company's primary markets and locations of manufacturing and logistics operations are the US, UK, Mexico, and Australia.

ROHTO PHARMACEUTICAL CO., LTD. manufactures and markets pharmaceuticals and cosmetics products.  The Company's products include eyewash, bath soaps, gastrointestinal medicine, and hand cream.  Rohto Pharmaceutical also has a license agreement with its subsidiary, Mentholatum (US) to sell their brand products.  The Company also manufactures contact lenses and health foods.

PT Kalbe Farma Tbk produces and develops pharmaceutical products for human and animal healthcare.  Through its subsidiaries, the Company also operates in the pharmaceutical, health food, and packaging industries.

Corcept Therapeutics Inc. is a pharmaceutical company that discovers and develops drugs for the treatment of severe metabolic and psychiatric disorders. The Company's lead product modulates the effect of cortisol, also known as the "stress hormone", by selectively blocking the binding of cortisol to one of its two known receptors, the GR-II receptor.

SANTEN PHARMACEUTICAL CO., LTD. produces and sells ophthalmic medicine.  The Company manufactures a variety of products including eye drops and ointments. Santen Pharmaceutical also imports lenses and tools and equipment used by optometrists and produces anti-rheumatic drugs.

Glaxosmithkline Pharmaceuticals Ltd. manufactures and distributes a wide variety of pharmaceutical drugs, veterinary products and laboratory chemicals. The Company's products include "Phexin" capsules, "Betnesol" tablets and injections, "Becoride" asthma treatment, "Betnovate" ointment, "Cetzine" antihistamine, "Zucox" and "Rizap" anti-tuberculosis products.

Glaxosmithkline Pharmaceuticals (GLXO IN)

Ajanta Pharma Limited is a pharmaceutical company involved in the areas of product research, manufacturing, and marketing. The Company's manufacturing capabilities include segments such as antiretrovirals, antimalarials, cardiovascular, dermatology, and ophthalmology. The Company also markets over the counter products that include some nature-based remedies.

Glenmark Pharmaceuticals Ltd., is a pharmaceutical company. The Company develops generic drugs for inflammation, metabolic disorders, and pain.

Yuhan Corporation manufactures and markets various pharmaceutical products on its own and through joint ventures with other global pharmaceutical companies. The Company also produces personal care products, dietary supplements, and veterinary medicines.

Prestige Brands Holdings, Inc. distributes over-the-counter healthcare and household cleaning products to retail stores in the United States, Canada and other international markets.  The Company distributes oral, eye and skin care; cough, cold, allergy and sinus; and household cleansers, sponges, scrubbers and cleaning pads.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a pharmaceutical company. Through its subsidiaries, the Company manufactures genetic medicines, Chinese traditional medicines, diagnostic products, and medical instruments, provides technology, marketing, and advertising services, as well as invests in import and export trading.

Shanghai Fosun Pharmaceutical (Group) (2196 HK)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Shanghai Fosun Pharmaceutical (Group) (2196 HK)

Quiddity Weekly H/A: Discounts & Southbound Flows 20180126

This is a new H/A Spread monitor project offering a brief look at recent changes in H-Share and A-Share spreads, Southbound flow and impact, and...

Travis Lundy

Quiddity Weekly H/A: Shares Discounts & Southbound Flows 20180112

This is a new H/A Spread monitor project which attempts to give a brief look at recent changes in H-Share and A-Share spreads based on various...

Travis Lundy

Global Pharmaceuticals: Valuations, Assets and Leverage Up - Margins Down

We examined ten years of accounting and valuation data for the pharmaceutical companies around the world with sales of US$100m+ and created...

Bucephalus Research Partnership

Sisram Medical IPO: Israeli Technology, China Story

Sisram Medical is raising up to USD174m in its Hong Kong listing. Sisram Medical is an Israel headquartered meditech company with backing from...

Ke Yan, CFA, FRM

Money Matters: A Fish Called Wanda

Any analysis of China's credit growth over the past six years or so would suggest that it is unsustainable and that as a result, when the day of...

Stewart Paterson

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)